MGUS and Myeloma: What’s the link?

Latest from the Blog

Improve the quality of your referral with GatewayC

Improve the quality of your referral with GatewayC

Friday 25th September 2020 Are you seeking to improve your suspected cancer referrals? Our Improving the Quality of Your Referral course aims to assist you with this and covers: Clinical decision making Helping to reduce DNAs Key information to include in a referral...

read more
Cancer Keys: Jaundice and Pancreatic Cancer

Cancer Keys: Jaundice and Pancreatic Cancer

Potential pitfall: Jaundice can be a classic symptom of pancreatic cancer; about half of patients have jaundice when they first go to their GP. Yet, pancreatic cancer is difficult to diagnose as symptoms can vary or may be late, vague and non-specific. Helpful hint:...

read more

Related Posts

Improve the quality of your referral with GatewayC

Improve the quality of your referral with GatewayC

Friday 25th September 2020 Are you seeking to improve your suspected cancer referrals? Our Improving the Quality of Your Referral course aims to assist you with this and covers: Clinical decision making Helping to reduce DNAs Key information to include in a referral...

read more
World Lymphoma Awareness Day

World Lymphoma Awareness Day

Tuesday 15th September 2020 It’s World Lymphoma Awareness Day. Why not increase your knowledge and complete our free online Lymphoma – Early Diagnosis course supported by Lymphoma Action? Lymphoma has many non-site specific symptoms and patients can often visit...

read more

MGUS is a benign condition which does not usually require treatment. However, a small number of patients diagnosed with MGUS will go on to develop myeloma.

Understanding MGUS

Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition characterised by the presence of paraproteins in the blood and/or urine. It doesn’t cause symptoms or require treatment and is usually only diagnosed when patients are investigated for other issues.

While most people with MGUS will not see an effect on their general health, about 1% of patients with MGUS will go on to develop myeloma each year.

Specialist viewpoint

The GatewayC Myeloma – Early Diagnosis course explores MGUS and its relationship with Myeloma in greater detail. GatewayC’s Cancer Lead GP, Dr. Sarah Taylor discusses the significance of this pre-malignant condition with Dr. Neil Rabin, Consultant Haematologist at University College London Hospitals and North Middlesex University Hospital NHS Trust.

What does Myeloma UK say about MGUS and Myeloma ?

MGUS is a condition which resembles myeloma due to the presence of abnormal plasma cells in the bone marrow and paraprotein in the blood and/or urine, but at much lower levels than in myeloma.

Each year around one in 100 MGUS patients will be diagnosed with myeloma and will need treatment. MGUS usually remains stable for many years without progressing to myeloma. Data suggests that if MGUS remains stable for two years then, on average, it will remain stable for 10 years before there is progression to myeloma.*

Cancer Key:

The presence of paraproteins in a patient’s blood or urine doesn’t necessarily mean they have myeloma and could be indicative of MGUS. However, it is important that these patients are sent to a haematologist, so that they can be appropriately investigated and be given advice on what symptoms to look out for.

Find out more: visit the GatewayC Myeloma – Early Diagnosis course here.

Keep up to date: Twitter | Facebook | LinkedIn

* Information from Myeloma UK – MGUS. See link here.